A Phase 2a clinical trial testing the safety of treatment candidate INS018_055 among idiopathic pulmonary fibrosis (IPF) patients in…
Articles by Lindsey Shapiro, PhD
The U.S. Food and Drug Administration (FDA) has approved Fibresolve, an AI or artificial intelligence-based software that’s designed to help…
Trevi Therapeutics has launched a Phase 2b clinical trial testing therapeutic candidate Haduvio (nalbuphine extended-release tablets) for the treatment…
The U.S. Food and Drug Administration (FDA) has given GRI Bio the green light to conduct a Phase 2…
Treatment with AP01, Avalyn Pharma‘s experimental inhaled formulation of pirfenidone, appears to be slightly more effective for idiopathic…
The first patients have been dosed in the Phase 2 REVERTIPF trial testing Tvardi Therapeutics’ investigational therapy TTI-101 in people with…
Scientists have developed a way to use engineered specialized stem cells to regenerate healthy airway tissues, offering a potential avenue…
Suppressing the production of a protein called NPAS2Â eased signs of lung scarring (fibrosis) in a mouse model of idiopathic…
Treatment with a molecule designed to activate the SHP-1 protein led to prolonged survival and alleviation of disease-associated lung changes…
The U.S. Food and Drug Administration has given the green light for Mabwell Therapeutics to launch a clinical trial…